OHARA Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Tokyo Japan (1964)
Status: No NME R&D (1964)

Organization Overview

First Clinical Trial
2019
NCT04047160
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ohara Pharmaceutical Co., Ltd. | OHARA Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

imatinib (gleevec) (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (1)

op-724 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangitis (Phase 1)

Fibrosis (Phase 1)

Hemophilia A (Phase 1)

Liver Cirrhosis (Phase 1)

Liver Cirrhosis, Biliary (Phase 1)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3